PMID- 35801423
OWN - NLM
STAT- MEDLINE
DCOM- 20230202
LR  - 20230208
IS  - 2831-090X (Electronic)
IS  - 2831-0896 (Print)
IS  - 2831-0896 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Feb 1
TI  - Circulating cytokine profile and modulation of regulatory T cells in chronic 
      hepatitis B patients with type 2 diabetes mellitus.
PG  - 53-62
LID - 10.17305/bjbms.2022.7525 [doi]
AB  - The risk of hepatitis B virus (HBV) infection is higher in patients with diabetes 
      mellitus, and diabetes mellitus is one of the metabolic complications of HBV 
      infection. However, the cytokine profile of chronic hepatitis B (CHB) patients 
      with type 2 diabetes mellitus (T2DM) is not fully understood. The aim of this 
      study was to investigate the cytokine expression profile in CHB patients with 
      T2DM, and to assess the regulatory function of cytokines to regulatory T cells 
      (Tregs). Forty-four T2DM patients, 39 CHB patients, 17 patients with CHB and 
      T2DM, and 21 control subjects were enrolled. Cytokine levels in the plasma were 
      measured by Luminex multiplex assay. CD4+CD25+CD127dim/- Tregs were detected by 
      flow cytometry. Tregs were purified and stimulated with recombinant human 
      interleukin-15 (IL-15). The regulation of IL-15 on Tregs function was 
      investigated by measuring cell number, IL-10/IL-35 secretion, and mRNA expression 
      of immune checkpoint molecules in a Tregs+PBMC co-culture system. We found that 
      levels of IL-1alpha, IL-6, and IL-33 were upregulated, while IFN-alpha, IL-2, IL-7, and 
      IL-15 were downregulated in T2DM and CHB patients. CHB patients with T2DM had 
      even lower plasma IL-7 and IL-15 levels. Tregs percentage was elevated in T2DM 
      and CHB patients. CHB patients with T2DM had increased levels of Tregs, which 
      correlated negatively with IL-15. Tregs showed stronger inhibitory activity in 
      CHB patients with T2DM than in controls, T2DM, and CHB patients, which presented 
      as reduction in cellular proliferation and induction of IL-10/IL-35 secretion. 
      IL-15 suppressed Tregs function and inhibited the expression of immune checkpoint 
      molecules in Tregs. The current data suggest that insufficient IL-15 levels and 
      decreased responsiveness of Tregs to IL-15 signaling might contribute to strong 
      immune dysfunction in CHB patients with T2DM.
FAU - He, Wang
AU  - He W
AD  - Department of Endocrinology, Xi'an No.1 Hospital, Xi'an, Shaanxi Province, China.
FAU - Hao, Shu
AU  - Hao S
AD  - Department of Endocrinology, Xi'an No.1 Hospital, Xi'an, Shaanxi Province, China.
FAU - Dong, Xiaohui
AU  - Dong X
AD  - Department of Endocrinology, Xi'an No.1 Hospital, Xi'an, Shaanxi Province, China.
FAU - Zhang, Dandan
AU  - Zhang D
AD  - Department of Endocrinology, Xi'an No.1 Hospital, Xi'an, Shaanxi Province, China.
FAU - Jia, Zhen
AU  - Jia Z
AD  - Department of Endocrinology, Xi'an No.1 Hospital, Xi'an, Shaanxi Province, China.
LA  - eng
PT  - Journal Article
DEP - 20230201
PL  - Bosnia and Herzegovina
TA  - Biomol Biomed
JT  - Biomolecules & biomedicine
JID - 9918522188506676
RN  - 130068-27-8 (Interleukin-10)
RN  - 0 (Interleukin-15)
RN  - 0 (Immune Checkpoint Proteins)
RN  - 0 (Interleukin-7)
RN  - 0 (Cytokines)
SB  - IM
MH  - Humans
MH  - *Hepatitis B, Chronic
MH  - Interleukin-10
MH  - Interleukin-15
MH  - T-Lymphocytes, Regulatory
MH  - *Diabetes Mellitus, Type 2
MH  - Immune Checkpoint Proteins
MH  - Leukocytes, Mononuclear
MH  - Interleukin-7
MH  - Hepatitis B virus
MH  - Cytokines
MH  - *Hepatitis B
PMC - PMC9901894
EDAT- 2022/07/09 06:00
MHDA- 2023/02/03 06:00
PMCR- 2023/02/01
CRDT- 2022/07/08 04:34
PHST- 2022/05/16 00:00 [received]
PHST- 2022/06/30 00:00 [accepted]
PHST- 2022/07/09 06:00 [pubmed]
PHST- 2023/02/03 06:00 [medline]
PHST- 2022/07/08 04:34 [entrez]
PHST- 2023/02/01 00:00 [pmc-release]
AID - BJBMS-22-326 [pii]
AID - 10.17305/bjbms.2022.7525 [doi]
PST - epublish
SO  - Biomol Biomed. 2023 Feb 1;23(1):53-62. doi: 10.17305/bjbms.2022.7525.